#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=Recognizing patients with monogenic
2-1	14-25	Recognizing	_	_	_	_
2-2	26-34	patients	person[2]	new[2]	ana	3-5[0_2]
2-3	35-39	with	person[2]	new[2]	_	_
2-4	40-49	monogenic	person[2]|abstract	new[2]|new	_	_

#Text=AIDs is difficult because their clinical spectrum may range from very mild inflammatory episodes to severe chronic disease .
3-1	50-54	AIDs	abstract	new	coref	10-6
3-2	55-57	is	_	_	_	_
3-3	58-67	difficult	_	_	_	_
3-4	68-75	because	_	_	_	_
3-5	76-81	their	person|abstract[6]	giv|new[6]	coref	5-19
3-6	82-90	clinical	abstract[6]	new[6]	_	_
3-7	91-99	spectrum	abstract[6]	new[6]	_	_
3-8	100-103	may	_	_	_	_
3-9	104-109	range	_	_	_	_
3-10	110-114	from	_	_	_	_
3-11	115-119	very	abstract[7]	new[7]	_	_
3-12	120-124	mild	abstract[7]	new[7]	_	_
3-13	125-137	inflammatory	abstract[7]	new[7]	_	_
3-14	138-146	episodes	abstract[7]	new[7]	_	_
3-15	147-149	to	abstract[7]	new[7]	_	_
3-16	150-156	severe	abstract[7]|abstract[8]	new[7]|new[8]	coref	4-3[9_8]
3-17	157-164	chronic	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-18	165-172	disease	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-19	173-174	.	_	_	_	_

#Text=Moreover , the disease features significantly overlap .
4-1	175-183	Moreover	_	_	_	_
4-2	184-185	,	_	_	_	_
4-3	186-189	the	abstract[9]	giv[9]	_	_
4-4	190-197	disease	abstract[9]	giv[9]	_	_
4-5	198-206	features	_	_	_	_
4-6	207-220	significantly	_	_	_	_
4-7	221-228	overlap	_	_	_	_
4-8	229-230	.	_	_	_	_

#Text=Our targeted NGS approach resulted in genetic confirmation in a relatively small proportion ( 7 % ) of patients .
5-1	231-234	Our	person|abstract[12]	acc|new[12]	ana|coref	6-29|19-4[122_12]
5-2	235-243	targeted	abstract[12]	new[12]	_	_
5-3	244-247	NGS	place|abstract[12]	new|new[12]	coref	12-10[80_0]
5-4	248-256	approach	abstract[12]	new[12]	_	_
5-5	257-265	resulted	abstract	new	none|none	5-5[0_179]|24-9
5-6	266-268	in	_	_	_	_
5-7	269-276	genetic	abstract[13]	new[13]	coref	18-15[110_13]
5-8	277-289	confirmation	abstract[13]	new[13]	_	_
5-9	290-292	in	abstract[13]	new[13]	_	_
5-10	293-294	a	abstract[13]|quantity[14]	new[13]|new[14]	appos	5-15[15_14]
5-11	295-305	relatively	abstract[13]|quantity[14]	new[13]|new[14]	_	_
5-12	306-311	small	abstract[13]|quantity[14]	new[13]|new[14]	_	_
5-13	312-322	proportion	abstract[13]|quantity[14]	new[13]|new[14]	_	_
5-14	323-324	(	_	_	_	_
5-15	325-326	7	quantity[15]	giv[15]	coref	23-8[154_15]
5-16	327-328	%	quantity[15]	giv[15]	_	_
5-17	329-330	)	_	_	_	_
5-18	331-333	of	_	_	_	_
5-19	334-342	patients	person	giv	coref	10-20[63_0]
5-20	343-344	.	_	_	_	_

#Text=This finding is consistent with two 2019 reports by Karacan et al. and Papa et al. , who used recent guidelines for the definition of positive diagnosis as we did .
6-1	345-349	This	abstract[17]	new[17]	_	_
6-2	350-357	finding	abstract[17]	new[17]	_	_
6-3	358-360	is	_	_	_	_
6-4	361-371	consistent	_	_	_	_
6-5	372-376	with	_	_	_	_
6-6	377-380	two	abstract[18]	new[18]	coref	8-2[31_18]
6-7	381-385	2019	abstract[18]	new[18]	_	_
6-8	386-393	reports	abstract[18]	new[18]	_	_
6-9	394-396	by	abstract[18]	new[18]	_	_
6-10	397-404	Karacan	abstract[18]|person	new[18]|new	_	_
6-11	405-407	et	abstract[18]	new[18]	_	_
6-12	408-411	al.	abstract[18]	new[18]	_	_
6-13	412-415	and	abstract[18]	new[18]	_	_
6-14	416-420	Papa	abstract[18]|person	new[18]|new	_	_
6-15	421-423	et	abstract[18]	new[18]	_	_
6-16	424-427	al.	abstract[18]	new[18]	_	_
6-17	428-429	,	_	_	_	_
6-18	430-433	who	_	_	_	_
6-19	434-438	used	_	_	_	_
6-20	439-445	recent	abstract[21]	new[21]	_	_
6-21	446-456	guidelines	abstract[21]	new[21]	_	_
6-22	457-460	for	abstract[21]	new[21]	_	_
6-23	461-464	the	abstract[21]|abstract[22]	new[21]|new[22]	coref	7-5[26_22]
6-24	465-475	definition	abstract[21]|abstract[22]	new[21]|new[22]	_	_
6-25	476-478	of	abstract[21]|abstract[22]	new[21]|new[22]	_	_
6-26	479-487	positive	abstract[21]|abstract[22]|abstract[23]	new[21]|new[22]|new[23]	coref	8-49[45_23]
6-27	488-497	diagnosis	abstract[21]|abstract[22]|abstract[23]	new[21]|new[22]|new[23]	_	_
6-28	498-500	as	_	_	_	_
6-29	501-503	we	person	giv	ana	9-3
6-30	504-507	did	_	_	_	_
6-31	508-509	.	_	_	_	_

#Text=Three previous studies using a broader definition claimed 19 % , 20 % , and 22 % diagnostic yield .
7-1	510-515	Three	event[25]	new[25]	_	_
7-2	516-524	previous	event[25]	new[25]	_	_
7-3	525-532	studies	event[25]	new[25]	_	_
7-4	533-538	using	_	_	_	_
7-5	539-540	a	abstract[26]	giv[26]	coref	9-3[47_26]
7-6	541-548	broader	abstract[26]	giv[26]	_	_
7-7	549-559	definition	abstract[26]	giv[26]	_	_
7-8	560-567	claimed	_	_	_	_
7-9	568-570	19	quantity[27]	new[27]	_	_
7-10	571-572	%	quantity[27]	new[27]	_	_
7-11	573-574	,	_	_	_	_
7-12	575-577	20	quantity[28]	new[28]	_	_
7-13	578-579	%	quantity[28]	new[28]	_	_
7-14	580-581	,	_	_	_	_
7-15	582-585	and	_	_	_	_
7-16	586-588	22	quantity[29]|abstract[30]	new[29]|new[30]	coref	15-13[104_30]
7-17	589-590	%	quantity[29]|abstract[30]	new[29]|new[30]	_	_
7-18	591-601	diagnostic	abstract[30]	new[30]	_	_
7-19	602-607	yield	abstract[30]	new[30]	_	_
7-20	608-609	.	_	_	_	_

#Text=In those reports , for example , frequent variants , such as p. ( Glu148Gln ) ( MEFV ) , p. ( Arg121Gln ) ( TNFRSF1A ) , or p. ( Val198Met ) ( NLRP3 ) , and all known susceptibility factors for inflammation were considered consistent with the diagnosis .
8-1	610-612	In	_	_	_	_
8-2	613-618	those	abstract[31]	giv[31]	_	_
8-3	619-626	reports	abstract[31]	giv[31]	_	_
8-4	627-628	,	_	_	_	_
8-5	629-632	for	_	_	_	_
8-6	633-640	example	_	_	_	_
8-7	641-642	,	_	_	_	_
8-8	643-651	frequent	object[32]	new[32]	coref	13-13[90_32]
8-9	652-660	variants	object[32]	new[32]	_	_
8-10	661-662	,	object[32]	new[32]	_	_
8-11	663-667	such	object[32]	new[32]	_	_
8-12	668-670	as	object[32]	new[32]	_	_
8-13	671-673	p.	object[32]|place	new[32]|new	coref	8-30
8-14	674-675	(	_	_	_	_
8-15	676-685	Glu148Gln	abstract	new	appos	8-18
8-16	686-687	)	_	_	_	_
8-17	688-689	(	_	_	_	_
8-18	690-694	MEFV	abstract	giv	coref	11-3[72_0]
8-19	695-696	)	_	_	_	_
8-20	697-698	,	_	_	_	_
8-21	699-701	p.	place	new	_	_
8-22	702-703	(	_	_	_	_
8-23	704-713	Arg121Gln	organization	new	_	_
8-24	714-715	)	_	_	_	_
8-25	716-717	(	_	_	_	_
8-26	718-726	TNFRSF1A	abstract	new	_	_
8-27	727-728	)	_	_	_	_
8-28	729-730	,	_	_	_	_
8-29	731-733	or	_	_	_	_
8-30	734-736	p.	place	giv	_	_
8-31	737-738	(	_	_	_	_
8-32	739-748	Val198Met	abstract	new	appos	8-35
8-33	749-750	)	_	_	_	_
8-34	751-752	(	_	_	_	_
8-35	753-758	NLRP3	abstract	giv	_	_
8-36	759-760	)	_	_	_	_
8-37	761-762	,	_	_	_	_
8-38	763-766	and	_	_	_	_
8-39	767-770	all	abstract[43]	new[43]	_	_
8-40	771-776	known	abstract[43]	new[43]	_	_
8-41	777-791	susceptibility	abstract|abstract[43]	new|new[43]	_	_
8-42	792-799	factors	abstract[43]	new[43]	_	_
8-43	800-803	for	abstract[43]	new[43]	_	_
8-44	804-816	inflammation	abstract[43]|abstract	new[43]|new	_	_
8-45	817-821	were	_	_	_	_
8-46	822-832	considered	_	_	_	_
8-47	833-843	consistent	_	_	_	_
8-48	844-848	with	_	_	_	_
8-49	849-852	the	abstract[45]	giv[45]	coref	9-22[51_45]
8-50	853-862	diagnosis	abstract[45]	giv[45]	_	_
8-51	863-864	.	_	_	_	_

#Text=Moreover , our definition was more stringent than these four previous studies because we considered that we could not conclude on the diagnosis when the parent ’s DNA was lacking segregation analyses of heterozygous rare VOUS .
9-1	865-873	Moreover	_	_	_	_
9-2	874-875	,	_	_	_	_
9-3	876-879	our	person|abstract[47]	giv|giv[47]	ana	9-14
9-4	880-890	definition	abstract[47]	giv[47]	_	_
9-5	891-894	was	_	_	_	_
9-6	895-899	more	_	_	_	_
9-7	900-909	stringent	_	_	_	_
9-8	910-914	than	_	_	_	_
9-9	915-920	these	abstract[48]	new[48]	_	_
9-10	921-925	four	abstract[48]	new[48]	_	_
9-11	926-934	previous	abstract[48]	new[48]	_	_
9-12	935-942	studies	abstract[48]	new[48]	_	_
9-13	943-950	because	_	_	_	_
9-14	951-953	we	person	giv	ana	9-17
9-15	954-964	considered	_	_	_	_
9-16	965-969	that	_	_	_	_
9-17	970-972	we	person	giv	ana	10-13
9-18	973-978	could	_	_	_	_
9-19	979-982	not	_	_	_	_
9-20	983-991	conclude	_	_	_	_
9-21	992-994	on	_	_	_	_
9-22	995-998	the	abstract[51]	giv[51]	coref	15-15[0_51]
9-23	999-1008	diagnosis	abstract[51]	giv[51]	_	_
9-24	1009-1013	when	_	_	_	_
9-25	1014-1017	the	abstract[53]	new[53]	_	_
9-26	1018-1024	parent	person[52]|abstract[53]	new[52]|new[53]	_	_
9-27	1025-1027	’s	person[52]|abstract[53]	new[52]|new[53]	_	_
9-28	1028-1031	DNA	abstract[53]	new[53]	_	_
9-29	1032-1035	was	_	_	_	_
9-30	1036-1043	lacking	_	_	_	_
9-31	1044-1055	segregation	abstract|abstract[55]	new|new[55]	coref	29-22
9-32	1056-1064	analyses	abstract[55]	new[55]	_	_
9-33	1065-1067	of	abstract[55]	new[55]	_	_
9-34	1068-1080	heterozygous	abstract[55]|abstract[56]	new[55]|new[56]	_	_
9-35	1081-1085	rare	abstract[55]|abstract[56]	new[55]|new[56]	_	_
9-36	1086-1090	VOUS	abstract[55]|abstract[56]	new[55]|new[56]	_	_
9-37	1091-1092	.	_	_	_	_

#Text=The low performance of the AIDs panel might also be explained by our study design that did not include most of the patients with features of FMF , MKD , and DADA2 because they were screened by Sanger sequencing .
10-1	1093-1096	The	abstract[57]	new[57]	coref	18-40[119_57]
10-2	1097-1100	low	abstract[57]	new[57]	_	_
10-3	1101-1112	performance	abstract[57]	new[57]	_	_
10-4	1113-1115	of	abstract[57]	new[57]	_	_
10-5	1116-1119	the	abstract[57]|object[59]	new[57]|new[59]	_	_
10-6	1120-1124	AIDs	abstract[57]|abstract|object[59]	new[57]|giv|new[59]	coref	12-18
10-7	1125-1130	panel	abstract[57]|object[59]	new[57]|new[59]	_	_
10-8	1131-1136	might	_	_	_	_
10-9	1137-1141	also	_	_	_	_
10-10	1142-1144	be	_	_	_	_
10-11	1145-1154	explained	_	_	_	_
10-12	1155-1157	by	_	_	_	_
10-13	1158-1161	our	person|event[62]	giv|new[62]	ana|coref	11-23|29-5[195_62]
10-14	1162-1167	study	object|event[62]	new|new[62]	coref	11-23[77_0]
10-15	1168-1174	design	event[62]	new[62]	_	_
10-16	1175-1179	that	_	_	_	_
10-17	1180-1183	did	_	_	_	_
10-18	1184-1187	not	_	_	_	_
10-19	1188-1195	include	_	_	_	_
10-20	1196-1200	most	person[63]	giv[63]	ana	10-34[0_63]
10-21	1201-1203	of	person[63]	giv[63]	_	_
10-22	1204-1207	the	person[63]	giv[63]	_	_
10-23	1208-1216	patients	person[63]	giv[63]	_	_
10-24	1217-1221	with	person[63]	giv[63]	_	_
10-25	1222-1230	features	person[63]|abstract[64]	giv[63]|new[64]	coref	26-11[177_64]
10-26	1231-1233	of	person[63]|abstract[64]	giv[63]|new[64]	_	_
10-27	1234-1237	FMF	person[63]|abstract[64]|abstract	giv[63]|new[64]|new	coref	13-4
10-28	1238-1239	,	person[63]|abstract[64]	giv[63]|new[64]	_	_
10-29	1240-1243	MKD	person[63]|abstract[64]|event	giv[63]|new[64]|new	_	_
10-30	1244-1245	,	person[63]|abstract[64]	giv[63]|new[64]	_	_
10-31	1246-1249	and	person[63]|abstract[64]	giv[63]|new[64]	_	_
10-32	1250-1255	DADA2	person[63]|abstract[64]|abstract	giv[63]|new[64]|new	_	_
10-33	1256-1263	because	_	_	_	_
10-34	1264-1268	they	person	giv	coref	14-4[95_0]
10-35	1269-1273	were	_	_	_	_
10-36	1274-1282	screened	_	_	_	_
10-37	1283-1285	by	_	_	_	_
10-38	1286-1292	Sanger	person|object[70]	new|new[70]	coref	33-49
10-39	1293-1303	sequencing	object[70]	new[70]	_	_
10-40	1304-1305	.	_	_	_	_

#Text=Still , the genes MEFV , MVK , and ADA2 remained among the four most frequently involved in the conclusive diagnoses of our study .
11-1	1306-1311	Still	_	_	_	_
11-2	1312-1313	,	_	_	_	_
11-3	1314-1317	the	abstract[71]|abstract[72]	new[71]|giv[72]	coref|coref	14-19[0_72]|31-21[213_71]
11-4	1318-1323	genes	abstract[71]|abstract[72]	new[71]|giv[72]	_	_
11-5	1324-1328	MEFV	abstract[72]	giv[72]	_	_
11-6	1329-1330	,	_	_	_	_
11-7	1331-1334	MVK	object	new	coref	33-16
11-8	1335-1336	,	_	_	_	_
11-9	1337-1340	and	_	_	_	_
11-10	1341-1345	ADA2	abstract	new	_	_
11-11	1346-1354	remained	_	_	_	_
11-12	1355-1360	among	_	_	_	_
11-13	1361-1364	the	_	_	_	_
11-14	1365-1369	four	_	_	_	_
11-15	1370-1374	most	_	_	_	_
11-16	1375-1385	frequently	_	_	_	_
11-17	1386-1394	involved	_	_	_	_
11-18	1395-1397	in	_	_	_	_
11-19	1398-1401	the	abstract[75]	new[75]	_	_
11-20	1402-1412	conclusive	abstract[75]	new[75]	_	_
11-21	1413-1422	diagnoses	abstract[75]	new[75]	_	_
11-22	1423-1425	of	abstract[75]	new[75]	_	_
11-23	1426-1429	our	abstract[75]|person|object[77]	new[75]|giv|giv[77]	ana|coref	15-2|24-3[158_77]
11-24	1430-1435	study	abstract[75]|object[77]	new[75]|giv[77]	_	_
11-25	1436-1437	.	_	_	_	_

#Text=This observation possibly stems from a better detection by NGS of the new molecular mechanisms involved in AIDs ( mosaicism , CNVs ) and better information on these three diseases because they are among the best-described AIDs .
12-1	1438-1442	This	event[78]	new[78]	_	_
12-2	1443-1454	observation	event[78]	new[78]	_	_
12-3	1455-1463	possibly	_	_	_	_
12-4	1464-1469	stems	_	_	_	_
12-5	1470-1474	from	_	_	_	_
12-6	1475-1476	a	abstract[79]	new[79]	_	_
12-7	1477-1483	better	abstract[79]	new[79]	_	_
12-8	1484-1493	detection	abstract[79]	new[79]	_	_
12-9	1494-1496	by	abstract[79]	new[79]	_	_
12-10	1497-1500	NGS	abstract[79]|place[80]	new[79]|giv[80]	coref	19-5[0_80]
12-11	1501-1503	of	abstract[79]|place[80]	new[79]|giv[80]	_	_
12-12	1504-1507	the	abstract[79]|place[80]|abstract[81]	new[79]|giv[80]|new[81]	coref	31-24[214_81]
12-13	1508-1511	new	abstract[79]|place[80]|abstract[81]	new[79]|giv[80]|new[81]	_	_
12-14	1512-1521	molecular	abstract[79]|place[80]|abstract[81]	new[79]|giv[80]|new[81]	_	_
12-15	1522-1532	mechanisms	abstract[79]|place[80]|abstract[81]	new[79]|giv[80]|new[81]	_	_
12-16	1533-1541	involved	_	_	_	_
12-17	1542-1544	in	_	_	_	_
12-18	1545-1549	AIDs	abstract	giv	coref	12-35[88_0]
12-19	1550-1551	(	_	_	_	_
12-20	1552-1561	mosaicism	abstract	new	_	_
12-21	1562-1563	,	_	_	_	_
12-22	1564-1568	CNVs	abstract	new	_	_
12-23	1569-1570	)	_	_	_	_
12-24	1571-1574	and	_	_	_	_
12-25	1575-1581	better	abstract[85]	new[85]	_	_
12-26	1582-1593	information	abstract[85]	new[85]	_	_
12-27	1594-1596	on	abstract[85]	new[85]	_	_
12-28	1597-1602	these	abstract[85]|abstract[86]	new[85]|new[86]	ana	12-32[0_86]
12-29	1603-1608	three	abstract[85]|abstract[86]	new[85]|new[86]	_	_
12-30	1609-1617	diseases	abstract[85]|abstract[86]	new[85]|new[86]	_	_
12-31	1618-1625	because	_	_	_	_
12-32	1626-1630	they	abstract	giv	_	_
12-33	1631-1634	are	_	_	_	_
12-34	1635-1640	among	_	_	_	_
12-35	1641-1644	the	abstract[88]	giv[88]	coref	19-26[0_88]
12-36	1645-1659	best-described	abstract[88]	giv[88]	_	_
12-37	1660-1664	AIDs	abstract[88]	giv[88]	_	_
12-38	1665-1666	.	_	_	_	_

#Text=In addition , FMF is now recognized as a disease caused by gain-of-function variants with a dosage effect rather than a purely recessive condition .
13-1	1667-1669	In	_	_	_	_
13-2	1670-1678	addition	_	_	_	_
13-3	1679-1680	,	_	_	_	_
13-4	1681-1684	FMF	abstract	giv	_	_
13-5	1685-1687	is	_	_	_	_
13-6	1688-1691	now	_	_	_	_
13-7	1692-1702	recognized	_	_	_	_
13-8	1703-1705	as	_	_	_	_
13-9	1706-1707	a	_	_	_	_
13-10	1708-1715	disease	_	_	_	_
13-11	1716-1722	caused	_	_	_	_
13-12	1723-1725	by	_	_	_	_
13-13	1726-1742	gain-of-function	object[90]	giv[90]	coref	33-29[235_90]
13-14	1743-1751	variants	object[90]	giv[90]	_	_
13-15	1752-1756	with	object[90]	giv[90]	_	_
13-16	1757-1758	a	object[90]|abstract[92]	giv[90]|new[92]	_	_
13-17	1759-1765	dosage	object[90]|abstract|abstract[92]	giv[90]|new|new[92]	_	_
13-18	1766-1772	effect	object[90]|abstract[92]	giv[90]|new[92]	_	_
13-19	1773-1779	rather	object[90]	giv[90]	_	_
13-20	1780-1784	than	object[90]	giv[90]	_	_
13-21	1785-1786	a	object[90]|abstract[93]	giv[90]|new[93]	coref	14-12[97_93]
13-22	1787-1793	purely	object[90]|abstract[93]	giv[90]|new[93]	_	_
13-23	1794-1803	recessive	object[90]|abstract[93]	giv[90]|new[93]	_	_
13-24	1804-1813	condition	object[90]|abstract[93]	giv[90]|new[93]	_	_
13-25	1814-1815	.	_	_	_	_

#Text=For one-third of the patients with one heterozygous pathogenic variant in a recessive condition , the gene was MEFV .
14-1	1816-1819	For	_	_	_	_
14-2	1820-1829	one-third	quantity[94]	new[94]	_	_
14-3	1830-1832	of	quantity[94]	new[94]	_	_
14-4	1833-1836	the	quantity[94]|person[95]	new[94]|giv[95]	coref	18-20[112_95]
14-5	1837-1845	patients	quantity[94]|person[95]	new[94]|giv[95]	_	_
14-6	1846-1850	with	quantity[94]	new[94]	_	_
14-7	1851-1854	one	quantity[94]|object[96]	new[94]|new[96]	coref	15-8[102_96]
14-8	1855-1867	heterozygous	quantity[94]|object[96]	new[94]|new[96]	_	_
14-9	1868-1878	pathogenic	quantity[94]|object[96]	new[94]|new[96]	_	_
14-10	1879-1886	variant	quantity[94]|object[96]	new[94]|new[96]	_	_
14-11	1887-1889	in	quantity[94]|object[96]	new[94]|new[96]	_	_
14-12	1890-1891	a	quantity[94]|object[96]|abstract[97]	new[94]|new[96]|giv[97]	_	_
14-13	1892-1901	recessive	quantity[94]|object[96]|abstract[97]	new[94]|new[96]|giv[97]	_	_
14-14	1902-1911	condition	quantity[94]|object[96]|abstract[97]	new[94]|new[96]|giv[97]	_	_
14-15	1912-1913	,	_	_	_	_
14-16	1914-1917	the	abstract[98]	new[98]	_	_
14-17	1918-1922	gene	abstract[98]	new[98]	_	_
14-18	1923-1926	was	_	_	_	_
14-19	1927-1931	MEFV	abstract	giv	_	_
14-20	1932-1933	.	_	_	_	_

#Text=If we had included heterozygous carriers of a MEFV pathogenic variant , the genetic diagnosis yield would have improved up to 10 % (
15-1	1934-1936	If	_	_	_	_
15-2	1937-1939	we	person	giv	ana	18-24
15-3	1940-1943	had	_	_	_	_
15-4	1944-1952	included	_	_	_	_
15-5	1953-1965	heterozygous	person[101]	new[101]	_	_
15-6	1966-1974	carriers	person[101]	new[101]	_	_
15-7	1975-1977	of	person[101]	new[101]	_	_
15-8	1978-1979	a	person[101]|object[102]	new[101]|giv[102]	coref	33-22[0_102]
15-9	1980-1984	MEFV	person[101]|object[102]	new[101]|giv[102]	_	_
15-10	1985-1995	pathogenic	person[101]|object[102]	new[101]|giv[102]	_	_
15-11	1996-2003	variant	person[101]|object[102]	new[101]|giv[102]	_	_
15-12	2004-2005	,	_	_	_	_
15-13	2006-2009	the	abstract[104]	giv[104]	_	_
15-14	2010-2017	genetic	abstract[104]	giv[104]	_	_
15-15	2018-2027	diagnosis	abstract|abstract[104]	giv|giv[104]	coref	26-5[175_0]
15-16	2028-2033	yield	abstract[104]	giv[104]	_	_
15-17	2034-2039	would	_	_	_	_
15-18	2040-2044	have	_	_	_	_
15-19	2045-2053	improved	_	_	_	_
15-20	2054-2056	up	_	_	_	_
15-21	2057-2059	to	_	_	_	_
15-22	2060-2062	10	quantity[105]	new[105]	_	_
15-23	2063-2064	%	quantity[105]	new[105]	_	_
15-24	2065-2066	(	_	_	_	_

#Text=Figure 2
16-1	2067-2073	Figure	abstract[106]	new[106]	_	_
16-2	2074-2075	2	abstract[106]	new[106]	_	_

#Text=) .
17-1	2076-2077	)	_	_	_	_
17-2	2078-2079	.	_	_	_	_

#Text=In an attempt to find a cause that could explain the low rate of genetic confirmation using panels in the patients referred to us , we wondered whether validation of the request by a specialized reference center could improve this performance .
18-1	2080-2082	In	_	_	_	_
18-2	2083-2085	an	abstract[107]	new[107]	_	_
18-3	2086-2093	attempt	abstract[107]	new[107]	_	_
18-4	2094-2096	to	_	_	_	_
18-5	2097-2101	find	abstract	new	coref|none	22-4[148_0]|18-5[0_148]
18-6	2102-2103	a	abstract[108]	new[108]	_	_
18-7	2104-2109	cause	abstract[108]	new[108]	_	_
18-8	2110-2114	that	_	_	_	_
18-9	2115-2120	could	_	_	_	_
18-10	2121-2128	explain	_	_	_	_
18-11	2129-2132	the	abstract[109]	new[109]	_	_
18-12	2133-2136	low	abstract[109]	new[109]	_	_
18-13	2137-2141	rate	abstract[109]	new[109]	_	_
18-14	2142-2144	of	abstract[109]	new[109]	_	_
18-15	2145-2152	genetic	abstract[109]|abstract[110]	new[109]|giv[110]	_	_
18-16	2153-2165	confirmation	abstract[109]|abstract[110]	new[109]|giv[110]	_	_
18-17	2166-2171	using	_	_	_	_
18-18	2172-2178	panels	person[111]	new[111]	coref	28-12[190_111]
18-19	2179-2181	in	person[111]	new[111]	_	_
18-20	2182-2185	the	person[111]|person[112]	new[111]|giv[112]	coref	19-24[127_112]
18-21	2186-2194	patients	person[111]|person[112]	new[111]|giv[112]	_	_
18-22	2195-2203	referred	_	_	_	_
18-23	2204-2206	to	_	_	_	_
18-24	2207-2209	us	person	giv	ana	18-26
18-25	2210-2211	,	_	_	_	_
18-26	2212-2214	we	person	giv	ana	21-1
18-27	2215-2223	wondered	_	_	_	_
18-28	2224-2231	whether	_	_	_	_
18-29	2232-2242	validation	abstract[115]	new[115]	_	_
18-30	2243-2245	of	abstract[115]	new[115]	_	_
18-31	2246-2249	the	abstract[115]|abstract[116]	new[115]|new[116]	_	_
18-32	2250-2257	request	abstract[115]|abstract[116]	new[115]|new[116]	_	_
18-33	2258-2260	by	abstract[115]|abstract[116]	new[115]|new[116]	_	_
18-34	2261-2262	a	abstract[115]|abstract[116]|place[118]	new[115]|new[116]|new[118]	coref	25-3[168_118]
18-35	2263-2274	specialized	abstract[115]|abstract[116]|place[118]	new[115]|new[116]|new[118]	_	_
18-36	2275-2284	reference	abstract[115]|abstract[116]|person|place[118]	new[115]|new[116]|new|new[118]	coref	20-2
18-37	2285-2291	center	abstract[115]|abstract[116]|place[118]	new[115]|new[116]|new[118]	_	_
18-38	2292-2297	could	_	_	_	_
18-39	2298-2305	improve	_	_	_	_
18-40	2306-2310	this	abstract[119]	giv[119]	_	_
18-41	2311-2322	performance	abstract[119]	giv[119]	_	_
18-42	2323-2324	.	_	_	_	_

#Text=The success of the NGS approach was suggested to rely on its use in the context of a highly specialized clinical service for patients with AIDs .
19-1	2325-2328	The	abstract[120]	new[120]	_	_
19-2	2329-2336	success	abstract[120]	new[120]	_	_
19-3	2337-2339	of	abstract[120]	new[120]	_	_
19-4	2340-2343	the	abstract[120]|abstract[122]	new[120]|giv[122]	ana	19-12[0_122]
19-5	2344-2347	NGS	abstract[120]|place|abstract[122]	new[120]|giv|giv[122]	coref	24-26
19-6	2348-2356	approach	abstract[120]|abstract[122]	new[120]|giv[122]	_	_
19-7	2357-2360	was	_	_	_	_
19-8	2361-2370	suggested	_	_	_	_
19-9	2371-2373	to	_	_	_	_
19-10	2374-2378	rely	_	_	_	_
19-11	2379-2381	on	_	_	_	_
19-12	2382-2385	its	abstract|abstract[124]	giv|new[124]	_	_
19-13	2386-2389	use	abstract[124]	new[124]	_	_
19-14	2390-2392	in	_	_	_	_
19-15	2393-2396	the	abstract[125]	new[125]	_	_
19-16	2397-2404	context	abstract[125]	new[125]	_	_
19-17	2405-2407	of	abstract[125]	new[125]	_	_
19-18	2408-2409	a	abstract[125]|abstract[126]	new[125]|new[126]	_	_
19-19	2410-2416	highly	abstract[125]|abstract[126]	new[125]|new[126]	_	_
19-20	2417-2428	specialized	abstract[125]|abstract[126]	new[125]|new[126]	_	_
19-21	2429-2437	clinical	abstract[125]|abstract[126]	new[125]|new[126]	_	_
19-22	2438-2445	service	abstract[125]|abstract[126]	new[125]|new[126]	_	_
19-23	2446-2449	for	abstract[125]|abstract[126]	new[125]|new[126]	_	_
19-24	2450-2458	patients	abstract[125]|abstract[126]|person[127]	new[125]|new[126]|giv[127]	coref	21-10[141_127]
19-25	2459-2463	with	abstract[125]|abstract[126]|person[127]	new[125]|new[126]|giv[127]	_	_
19-26	2464-2468	AIDs	abstract[125]|abstract[126]|person[127]|abstract	new[125]|new[126]|giv[127]|giv	coref	21-11
19-27	2469-2470	.	_	_	_	_

#Text=National reference centers and networks cover all the expertise necessary for patient care and operational management and efficiency .
20-1	2471-2479	National	place[130]	new[130]	coref	21-16[144_130]
20-2	2480-2489	reference	person|place[130]	giv|new[130]	coref	21-16
20-3	2490-2497	centers	place[130]	new[130]	_	_
20-4	2498-2501	and	_	_	_	_
20-5	2502-2510	networks	place	new	_	_
20-6	2511-2516	cover	_	_	_	_
20-7	2517-2520	all	abstract[132]	new[132]	_	_
20-8	2521-2524	the	abstract[132]	new[132]	_	_
20-9	2525-2534	expertise	abstract[132]	new[132]	_	_
20-10	2535-2544	necessary	abstract[132]	new[132]	_	_
20-11	2545-2548	for	_	_	_	_
20-12	2549-2556	patient	person|abstract[134]	new|new[134]	coref	34-18[252_0]
20-13	2557-2561	care	abstract[134]	new[134]	_	_
20-14	2562-2565	and	_	_	_	_
20-15	2566-2577	operational	abstract[135]	new[135]	_	_
20-16	2578-2588	management	abstract[135]	new[135]	_	_
20-17	2589-2592	and	_	_	_	_
20-18	2593-2603	efficiency	abstract	new	_	_
20-19	2604-2605	.	_	_	_	_

#Text=We established a pre-requisite for a systematic evaluation of undifferentiated AIDs patients by clinicians from reference centers .
21-1	2606-2608	We	person	giv	ana	24-3
21-2	2609-2620	established	_	_	_	_
21-3	2621-2622	a	abstract[138]	new[138]	_	_
21-4	2623-2636	pre-requisite	abstract[138]	new[138]	_	_
21-5	2637-2640	for	abstract[138]	new[138]	_	_
21-6	2641-2642	a	abstract[138]|event[139]	new[138]|new[139]	_	_
21-7	2643-2653	systematic	abstract[138]|event[139]	new[138]|new[139]	_	_
21-8	2654-2664	evaluation	abstract[138]|event[139]	new[138]|new[139]	_	_
21-9	2665-2667	of	abstract[138]|event[139]	new[138]|new[139]	_	_
21-10	2668-2684	undifferentiated	abstract[138]|event[139]|person[141]	new[138]|new[139]|giv[141]	coref	22-17[151_141]
21-11	2685-2689	AIDs	abstract[138]|event[139]|abstract|person[141]	new[138]|new[139]|giv|giv[141]	coref	27-24
21-12	2690-2698	patients	abstract[138]|event[139]|person[141]	new[138]|new[139]|giv[141]	_	_
21-13	2699-2701	by	abstract[138]|event[139]|person[141]	new[138]|new[139]|giv[141]	_	_
21-14	2702-2712	clinicians	abstract[138]|event[139]|person[141]|person[142]	new[138]|new[139]|giv[141]|new[142]	coref	32-10[221_142]
21-15	2713-2717	from	abstract[138]|event[139]|person[141]|person[142]	new[138]|new[139]|giv[141]|new[142]	_	_
21-16	2718-2727	reference	abstract[138]|event[139]|person[141]|person[142]|person|place[144]	new[138]|new[139]|giv[141]|new[142]|giv|giv[144]	coref|coref	22-8[147_144]|25-4
21-17	2728-2735	centers	abstract[138]|event[139]|person[141]|person[142]|place[144]	new[138]|new[139]|giv[141]|new[142]|giv[144]	_	_
21-18	2736-2737	.	_	_	_	_

#Text=It is possible that many doctors from non-reference centers could not find the time to present their patients to MSM .
22-1	2738-2740	It	abstract	new	cata	22-1[0_148]
22-2	2741-2743	is	_	_	_	_
22-3	2744-2752	possible	_	_	_	_
22-4	2753-2757	that	abstract[148]	new[148]	_	_
22-5	2758-2762	many	person[146]|abstract[148]	new[146]|new[148]	ana	22-17[0_146]
22-6	2763-2770	doctors	person[146]|abstract[148]	new[146]|new[148]	_	_
22-7	2771-2775	from	person[146]|abstract[148]	new[146]|new[148]	_	_
22-8	2776-2789	non-reference	person[146]|place[147]|abstract[148]	new[146]|giv[147]|new[148]	coref	23-14[156_147]
22-9	2790-2797	centers	person[146]|place[147]|abstract[148]	new[146]|giv[147]|new[148]	_	_
22-10	2798-2803	could	abstract[148]	new[148]	_	_
22-11	2804-2807	not	abstract[148]	new[148]	_	_
22-12	2808-2812	find	abstract[148]	new[148]	_	_
22-13	2813-2816	the	abstract[148]|time[149]	new[148]|new[149]	coref	32-14[223_149]
22-14	2817-2821	time	abstract[148]|time[149]	new[148]|new[149]	_	_
22-15	2822-2824	to	_	_	_	_
22-16	2825-2832	present	_	_	_	_
22-17	2833-2838	their	person|person[151]	giv|giv[151]	coref	23-11[0_151]
22-18	2839-2847	patients	person[151]	giv[151]	_	_
22-19	2848-2850	to	_	_	_	_
22-20	2851-2854	MSM	abstract	new	coref	34-5[249_0]
22-21	2855-2856	.	_	_	_	_

#Text=This certainly accounts for the decrease in the proportion of patients referred by the non-reference centers .
23-1	2857-2861	This	_	_	_	_
23-2	2862-2871	certainly	_	_	_	_
23-3	2872-2880	accounts	_	_	_	_
23-4	2881-2884	for	_	_	_	_
23-5	2885-2888	the	event[153]	new[153]	_	_
23-6	2889-2897	decrease	event[153]	new[153]	_	_
23-7	2898-2900	in	event[153]	new[153]	_	_
23-8	2901-2904	the	event[153]|quantity[154]	new[153]|giv[154]	_	_
23-9	2905-2915	proportion	event[153]|quantity[154]	new[153]|giv[154]	_	_
23-10	2916-2918	of	event[153]|quantity[154]	new[153]|giv[154]	_	_
23-11	2919-2927	patients	event[153]|quantity[154]|person	new[153]|giv[154]|giv	coref	26-2[174_0]
23-12	2928-2936	referred	_	_	_	_
23-13	2937-2939	by	_	_	_	_
23-14	2940-2943	the	place[156]	giv[156]	coref	35-4[256_156]
23-15	2944-2957	non-reference	place[156]	giv[156]	_	_
23-16	2958-2965	centers	place[156]	giv[156]	_	_
23-17	2966-2967	.	_	_	_	_

#Text=However , our study showed that this strategy resulted in a better clinical filter for ordering genetic tests and almost doubled the performance of our NGS strategy .
24-1	2968-2975	However	_	_	_	_
24-2	2976-2977	,	_	_	_	_
24-3	2978-2981	our	person|object[158]	giv|giv[158]	ana|coref	24-25|29-6[0_158]
24-4	2982-2987	study	object[158]	giv[158]	_	_
24-5	2988-2994	showed	_	_	_	_
24-6	2995-2999	that	_	_	_	_
24-7	3000-3004	this	abstract[159]	new[159]	coref	24-25[165_159]
24-8	3005-3013	strategy	abstract[159]	new[159]	_	_
24-9	3014-3022	resulted	abstract	new	coref	27-1[179_0]
24-10	3023-3025	in	_	_	_	_
24-11	3026-3027	a	object[160]	new[160]	_	_
24-12	3028-3034	better	object[160]	new[160]	_	_
24-13	3035-3043	clinical	object[160]	new[160]	_	_
24-14	3044-3050	filter	object[160]	new[160]	_	_
24-15	3051-3054	for	_	_	_	_
24-16	3055-3063	ordering	_	_	_	_
24-17	3064-3071	genetic	object[161]	new[161]	coref	25-21[172_161]
24-18	3072-3077	tests	object[161]	new[161]	_	_
24-19	3078-3081	and	_	_	_	_
24-20	3082-3088	almost	_	_	_	_
24-21	3089-3096	doubled	_	_	_	_
24-22	3097-3100	the	abstract[162]	new[162]	_	_
24-23	3101-3112	performance	abstract[162]	new[162]	_	_
24-24	3113-3115	of	abstract[162]	new[162]	_	_
24-25	3116-3119	our	abstract[162]|person|abstract[165]	new[162]|giv|giv[165]	ana|coref	25-3|34-10[250_165]
24-26	3120-3123	NGS	abstract[162]|event|abstract[165]	new[162]|giv|giv[165]	coref	28-12
24-27	3124-3132	strategy	abstract[162]|abstract[165]	new[162]|giv[165]	_	_
24-28	3133-3134	.	_	_	_	_

#Text=Also , our reference center recently offered a diagnostic checklist to guide practitioners who may suspect an AID for ordering genetic tests .
25-1	3135-3139	Also	_	_	_	_
25-2	3140-3141	,	_	_	_	_
25-3	3142-3145	our	person|place[168]	giv|giv[168]	ana	26-2
25-4	3146-3155	reference	person|place[168]	giv|giv[168]	coref	35-5
25-5	3156-3162	center	place[168]	giv[168]	_	_
25-6	3163-3171	recently	_	_	_	_
25-7	3172-3179	offered	_	_	_	_
25-8	3180-3181	a	abstract[169]	new[169]	_	_
25-9	3182-3192	diagnostic	abstract[169]	new[169]	_	_
25-10	3193-3202	checklist	abstract[169]	new[169]	_	_
25-11	3203-3205	to	_	_	_	_
25-12	3206-3211	guide	_	_	_	_
25-13	3212-3225	practitioners	person	new	_	_
25-14	3226-3229	who	_	_	_	_
25-15	3230-3233	may	_	_	_	_
25-16	3234-3241	suspect	_	_	_	_
25-17	3242-3244	an	abstract[171]	new[171]	coref	26-9[0_171]
25-18	3245-3248	AID	abstract[171]	new[171]	_	_
25-19	3249-3252	for	_	_	_	_
25-20	3253-3261	ordering	_	_	_	_
25-21	3262-3269	genetic	abstract[172]	giv[172]	_	_
25-22	3270-3275	tests	abstract[172]	giv[172]	_	_
25-23	3276-3277	.	_	_	_	_

#Text=In our patients with a conclusive diagnosis of AID , the main features identified were mucocutaneous , articular , and gastro-intestinal .
26-1	3278-3280	In	_	_	_	_
26-2	3281-3284	our	person|person[174]	giv|giv[174]	ana|coref	28-1|29-11[197_174]
26-3	3285-3293	patients	person[174]	giv[174]	_	_
26-4	3294-3298	with	person[174]	giv[174]	_	_
26-5	3299-3300	a	person[174]|abstract[175]	giv[174]|giv[175]	coref	31-34[217_175]
26-6	3301-3311	conclusive	person[174]|abstract[175]	giv[174]|giv[175]	_	_
26-7	3312-3321	diagnosis	person[174]|abstract[175]	giv[174]|giv[175]	_	_
26-8	3322-3324	of	person[174]|abstract[175]	giv[174]|giv[175]	_	_
26-9	3325-3328	AID	person[174]|abstract[175]|abstract	giv[174]|giv[175]|giv	coref	35-19[258_0]
26-10	3329-3330	,	_	_	_	_
26-11	3331-3334	the	abstract[177]	giv[177]	_	_
26-12	3335-3339	main	abstract[177]	giv[177]	_	_
26-13	3340-3348	features	abstract[177]	giv[177]	_	_
26-14	3349-3359	identified	_	_	_	_
26-15	3360-3364	were	_	_	_	_
26-16	3365-3378	mucocutaneous	_	_	_	_
26-17	3379-3380	,	_	_	_	_
26-18	3381-3390	articular	_	_	_	_
26-19	3391-3392	,	_	_	_	_
26-20	3393-3396	and	_	_	_	_
26-21	3397-3414	gastro-intestinal	person	new	_	_
26-22	3415-3416	.	_	_	_	_

#Text=This result reflects daily practice because the cutaneous/mucosal , digestive tract , and musculoskeletal systems are the three most common systems involved in AIDs .
27-1	3417-3421	This	abstract[179]	new[179]	_	_
27-2	3422-3428	result	abstract[179]	new[179]	_	_
27-3	3429-3437	reflects	_	_	_	_
27-4	3438-3443	daily	abstract[180]	new[180]	_	_
27-5	3444-3452	practice	abstract[180]	new[180]	_	_
27-6	3453-3460	because	_	_	_	_
27-7	3461-3464	the	abstract[181]	new[181]	_	_
27-8	3465-3482	cutaneous/mucosal	abstract[181]	new[181]	_	_
27-9	3483-3484	,	_	_	_	_
27-10	3485-3494	digestive	object[182]	new[182]	_	_
27-11	3495-3500	tract	object[182]	new[182]	_	_
27-12	3501-3502	,	_	_	_	_
27-13	3503-3506	and	_	_	_	_
27-14	3507-3522	musculoskeletal	abstract[183]	new[183]	coref	27-17[184_183]
27-15	3523-3530	systems	abstract[183]	new[183]	_	_
27-16	3531-3534	are	_	_	_	_
27-17	3535-3538	the	abstract[184]	giv[184]	ana	29-9[196_184]
27-18	3539-3544	three	abstract[184]	giv[184]	_	_
27-19	3545-3549	most	abstract[184]	giv[184]	_	_
27-20	3550-3556	common	abstract[184]	giv[184]	_	_
27-21	3557-3564	systems	abstract[184]	giv[184]	_	_
27-22	3565-3573	involved	_	_	_	_
27-23	3574-3576	in	_	_	_	_
27-24	3577-3581	AIDs	abstract	giv	coref	28-15[191_0]
27-25	3582-3583	.	_	_	_	_

#Text=We cannot rule out a relative underestimation of the potential of NGS panels for AIDs in general .
28-1	3584-3586	We	person	giv	ana	29-5
28-2	3587-3593	cannot	_	_	_	_
28-3	3594-3598	rule	_	_	_	_
28-4	3599-3602	out	_	_	_	_
28-5	3603-3604	a	abstract[187]	new[187]	_	_
28-6	3605-3613	relative	abstract[187]	new[187]	_	_
28-7	3614-3629	underestimation	abstract[187]	new[187]	_	_
28-8	3630-3632	of	abstract[187]	new[187]	_	_
28-9	3633-3636	the	abstract[187]|abstract[188]	new[187]|new[188]	_	_
28-10	3637-3646	potential	abstract[187]|abstract[188]	new[187]|new[188]	_	_
28-11	3647-3649	of	abstract[187]|abstract[188]	new[187]|new[188]	_	_
28-12	3650-3653	NGS	abstract[187]|abstract[188]|abstract|person[190]	new[187]|new[188]|giv|giv[190]	coref	29-20
28-13	3654-3660	panels	abstract[187]|abstract[188]|person[190]	new[187]|new[188]|giv[190]	_	_
28-14	3661-3664	for	abstract[187]|abstract[188]|person[190]	new[187]|new[188]|giv[190]	_	_
28-15	3665-3669	AIDs	abstract[187]|abstract[188]|person[190]|abstract[191]	new[187]|new[188]|giv[190]|giv[191]	coref	31-28[0_191]
28-16	3670-3672	in	abstract[187]|abstract[188]|person[190]|abstract[191]	new[187]|new[188]|giv[190]|giv[191]	_	_
28-17	3673-3680	general	abstract[187]|abstract[188]|person[190]|abstract[191]|person	new[187]|new[188]|giv[190]|giv[191]|new	_	_
28-18	3681-3682	.	_	_	_	_

#Text=Indeed , because of our study design , some of the patients or their relatives were not available for NGS or segregation analysis .
29-1	3683-3689	Indeed	_	_	_	_
29-2	3690-3691	,	_	_	_	_
29-3	3692-3699	because	_	_	_	_
29-4	3700-3702	of	_	_	_	_
29-5	3703-3706	our	person|abstract[195]	giv|giv[195]	ana	30-3
29-6	3707-3712	study	object|abstract[195]	giv|giv[195]	_	_
29-7	3713-3719	design	abstract[195]	giv[195]	_	_
29-8	3720-3721	,	_	_	_	_
29-9	3722-3726	some	abstract[196]	giv[196]	_	_
29-10	3727-3729	of	abstract[196]	giv[196]	_	_
29-11	3730-3733	the	abstract[196]|person[197]	giv[196]|giv[197]	coref	33-32[236_197]
29-12	3734-3742	patients	abstract[196]|person[197]	giv[196]|giv[197]	_	_
29-13	3743-3745	or	abstract[196]|person[197]	giv[196]|giv[197]	_	_
29-14	3746-3751	their	abstract[196]|person[197]|person[198]	giv[196]|giv[197]|new[198]	_	_
29-15	3752-3761	relatives	abstract[196]|person[197]|person[198]	giv[196]|giv[197]|new[198]	_	_
29-16	3762-3766	were	_	_	_	_
29-17	3767-3770	not	_	_	_	_
29-18	3771-3780	available	_	_	_	_
29-19	3781-3784	for	_	_	_	_
29-20	3785-3788	NGS	abstract|abstract[201]	giv|new[201]	coref	30-13
29-21	3789-3791	or	abstract[201]	new[201]	_	_
29-22	3792-3803	segregation	abstract|abstract[201]	giv|new[201]	_	_
29-23	3804-3812	analysis	abstract[201]	new[201]	_	_
29-24	3813-3814	.	_	_	_	_

#Text=However , our aim was not to evaluate the exact performance of NGS but to find ways to improve it .
30-1	3815-3822	However	_	_	_	_
30-2	3823-3824	,	_	_	_	_
30-3	3825-3828	our	person|abstract[203]	giv|new[203]	ana	31-8
30-4	3829-3832	aim	abstract[203]	new[203]	_	_
30-5	3833-3836	was	_	_	_	_
30-6	3837-3840	not	_	_	_	_
30-7	3841-3843	to	_	_	_	_
30-8	3844-3852	evaluate	_	_	_	_
30-9	3853-3856	the	abstract[204]	new[204]	ana	30-20[0_204]
30-10	3857-3862	exact	abstract[204]	new[204]	_	_
30-11	3863-3874	performance	abstract[204]	new[204]	_	_
30-12	3875-3877	of	abstract[204]	new[204]	_	_
30-13	3878-3881	NGS	abstract[204]|place	new[204]|giv	coref	36-22[263_0]
30-14	3882-3885	but	_	_	_	_
30-15	3886-3888	to	_	_	_	_
30-16	3889-3893	find	_	_	_	_
30-17	3894-3898	ways	abstract	new	_	_
30-18	3899-3901	to	_	_	_	_
30-19	3902-3909	improve	_	_	_	_
30-20	3910-3912	it	abstract	giv	_	_
30-21	3913-3914	.	_	_	_	_

#Text=In addition to the successful clinical option we demonstrated here , it is easy to predict the upcoming discovery of new genes or molecular mechanisms involved in AIDs that will continue to revolutionize our routine genetic diagnosis .
31-1	3915-3917	In	_	_	_	_
31-2	3918-3926	addition	_	_	_	_
31-3	3927-3929	to	_	_	_	_
31-4	3930-3933	the	abstract[208]	new[208]	_	_
31-5	3934-3944	successful	abstract[208]	new[208]	_	_
31-6	3945-3953	clinical	abstract[208]	new[208]	_	_
31-7	3954-3960	option	abstract[208]	new[208]	_	_
31-8	3961-3963	we	person	giv	ana	31-34
31-9	3964-3976	demonstrated	_	_	_	_
31-10	3977-3981	here	_	_	_	_
31-11	3982-3983	,	_	_	_	_
31-12	3984-3986	it	abstract	new	cata	31-12[0_211]
31-13	3987-3989	is	_	_	_	_
31-14	3990-3994	easy	_	_	_	_
31-15	3995-3997	to	abstract[211]	new[211]	_	_
31-16	3998-4005	predict	abstract[211]	new[211]	_	_
31-17	4006-4009	the	abstract[211]|abstract[212]	new[211]|new[212]	_	_
31-18	4010-4018	upcoming	abstract[211]|abstract[212]	new[211]|new[212]	_	_
31-19	4019-4028	discovery	abstract[211]|abstract[212]	new[211]|new[212]	_	_
31-20	4029-4031	of	abstract[211]|abstract[212]	new[211]|new[212]	_	_
31-21	4032-4035	new	abstract[211]|abstract[212]|abstract[213]	new[211]|new[212]|giv[213]	coref	33-69[245_213]
31-22	4036-4041	genes	abstract[211]|abstract[212]|abstract[213]	new[211]|new[212]|giv[213]	_	_
31-23	4042-4044	or	abstract[211]|abstract[212]|abstract[213]	new[211]|new[212]|giv[213]	_	_
31-24	4045-4054	molecular	abstract[211]|abstract[212]|abstract[213]|abstract[214]	new[211]|new[212]|giv[213]|giv[214]	_	_
31-25	4055-4065	mechanisms	abstract[211]|abstract[212]|abstract[213]|abstract[214]	new[211]|new[212]|giv[213]|giv[214]	_	_
31-26	4066-4074	involved	_	_	_	_
31-27	4075-4077	in	_	_	_	_
31-28	4078-4082	AIDs	abstract	giv	_	_
31-29	4083-4087	that	_	_	_	_
31-30	4088-4092	will	_	_	_	_
31-31	4093-4101	continue	_	_	_	_
31-32	4102-4104	to	_	_	_	_
31-33	4105-4118	revolutionize	_	_	_	_
31-34	4119-4122	our	person|abstract[217]	giv|giv[217]	_	_
31-35	4123-4130	routine	abstract[217]	giv[217]	_	_
31-36	4131-4138	genetic	abstract[217]	giv[217]	_	_
31-37	4139-4148	diagnosis	abstract[217]	giv[217]	_	_
31-38	4149-4150	.	_	_	_	_

#Text=Recent inputs of the literature advocate closer interactions between clinicians and geneticists in the era of whole-genome sequencing .
32-1	4151-4157	Recent	abstract[218]	new[218]	_	_
32-2	4158-4164	inputs	abstract[218]	new[218]	_	_
32-3	4165-4167	of	abstract[218]	new[218]	_	_
32-4	4168-4171	the	abstract[218]|abstract[219]	new[218]|new[219]	_	_
32-5	4172-4182	literature	abstract[218]|abstract[219]	new[218]|new[219]	_	_
32-6	4183-4191	advocate	_	_	_	_
32-7	4192-4198	closer	abstract[220]	new[220]	ana	33-2[0_220]
32-8	4199-4211	interactions	abstract[220]	new[220]	_	_
32-9	4212-4219	between	abstract[220]	new[220]	_	_
32-10	4220-4230	clinicians	abstract[220]|person[221]	new[220]|giv[221]	_	_
32-11	4231-4234	and	abstract[220]|person[221]	new[220]|giv[221]	_	_
32-12	4235-4246	geneticists	abstract[220]|person[221]|person[222]	new[220]|giv[221]|new[222]	coref	37-21[0_222]
32-13	4247-4249	in	abstract[220]|person[221]|person[222]	new[220]|giv[221]|new[222]	_	_
32-14	4250-4253	the	abstract[220]|person[221]|person[222]|time[223]	new[220]|giv[221]|new[222]|giv[223]	_	_
32-15	4254-4257	era	abstract[220]|person[221]|person[222]|time[223]	new[220]|giv[221]|new[222]|giv[223]	_	_
32-16	4258-4260	of	abstract[220]|person[221]|person[222]|time[223]	new[220]|giv[221]|new[222]|giv[223]	_	_
32-17	4261-4273	whole-genome	abstract[220]|person[221]|person[222]|time[223]|object[224]	new[220]|giv[221]|new[222]|giv[223]|new[224]	_	_
32-18	4274-4284	sequencing	abstract[220]|person[221]|person[222]|time[223]|object[224]	new[220]|giv[221]|new[222]|giv[223]|new[224]	_	_
32-19	4285-4286	.	_	_	_	_

#Text=Among them are the identification of genetic modifiers , affecting the penetrance of homozygous pathogenic MVK : p. ( Val377Ile ) variant ; the lack of detection of pathogenic variants in patients with a clear given phenotype , such as pathogenic canonical splice site variants not covered by Sanger and panel approaches ( e. g. , ADA2 : c. -47+2T>C ) ; or large chromosomal rearrangements , encompassing several genes in patients with complex phenotypes .
33-1	4287-4292	Among	_	_	_	_
33-2	4293-4297	them	abstract	giv	coref	33-4[226_0]
33-3	4298-4301	are	_	_	_	_
33-4	4302-4305	the	abstract[226]	giv[226]	_	_
33-5	4306-4320	identification	abstract[226]	giv[226]	_	_
33-6	4321-4323	of	abstract[226]	giv[226]	_	_
33-7	4324-4331	genetic	abstract[226]|abstract[227]	giv[226]|new[227]	_	_
33-8	4332-4341	modifiers	abstract[226]|abstract[227]	giv[226]|new[227]	_	_
33-9	4342-4343	,	_	_	_	_
33-10	4344-4353	affecting	_	_	_	_
33-11	4354-4357	the	abstract[228]	new[228]	_	_
33-12	4358-4368	penetrance	abstract[228]	new[228]	_	_
33-13	4369-4371	of	abstract[228]	new[228]	_	_
33-14	4372-4382	homozygous	abstract[228]|abstract[229]	new[228]|new[229]	_	_
33-15	4383-4393	pathogenic	abstract[228]|abstract[229]	new[228]|new[229]	_	_
33-16	4394-4397	MVK	abstract[228]|abstract	new[228]|giv	_	_
33-17	4398-4399	:	_	_	_	_
33-18	4400-4402	p.	_	_	_	_
33-19	4403-4404	(	_	_	_	_
33-20	4405-4414	Val377Ile	abstract	new	_	_
33-21	4415-4416	)	_	_	_	_
33-22	4417-4424	variant	object	giv	_	_
33-23	4425-4426	;	_	_	_	_
33-24	4427-4430	the	abstract[233]	new[233]	_	_
33-25	4431-4435	lack	abstract[233]	new[233]	_	_
33-26	4436-4438	of	abstract[233]	new[233]	_	_
33-27	4439-4448	detection	abstract[233]|abstract[234]	new[233]|new[234]	_	_
33-28	4449-4451	of	abstract[233]|abstract[234]	new[233]|new[234]	_	_
33-29	4452-4462	pathogenic	abstract[233]|abstract[234]|object[235]	new[233]|new[234]|giv[235]	_	_
33-30	4463-4471	variants	abstract[233]|abstract[234]|object[235]	new[233]|new[234]|giv[235]	_	_
33-31	4472-4474	in	abstract[233]|abstract[234]|object[235]	new[233]|new[234]|giv[235]	_	_
33-32	4475-4483	patients	abstract[233]|abstract[234]|object[235]|person[236]	new[233]|new[234]|giv[235]|giv[236]	coref	33-72[246_236]
33-33	4484-4488	with	abstract[233]|abstract[234]|object[235]|person[236]	new[233]|new[234]|giv[235]|giv[236]	_	_
33-34	4489-4490	a	abstract[233]|abstract[234]|object[235]|person[236]|abstract[237]	new[233]|new[234]|giv[235]|giv[236]|new[237]	coref	34-17[253_237]
33-35	4491-4496	clear	abstract[233]|abstract[234]|object[235]|person[236]|abstract[237]	new[233]|new[234]|giv[235]|giv[236]|new[237]	_	_
33-36	4497-4502	given	abstract[233]|abstract[234]|object[235]|person[236]|abstract[237]	new[233]|new[234]|giv[235]|giv[236]|new[237]	_	_
33-37	4503-4512	phenotype	abstract[233]|abstract[234]|object[235]|person[236]|abstract[237]	new[233]|new[234]|giv[235]|giv[236]|new[237]	_	_
33-38	4513-4514	,	abstract[233]|abstract[234]|object[235]|person[236]|abstract[237]	new[233]|new[234]|giv[235]|giv[236]|new[237]	_	_
33-39	4515-4519	such	abstract[233]|abstract[234]|object[235]|person[236]|abstract[237]	new[233]|new[234]|giv[235]|giv[236]|new[237]	_	_
33-40	4520-4522	as	abstract[233]|abstract[234]|object[235]|person[236]|abstract[237]	new[233]|new[234]|giv[235]|giv[236]|new[237]	_	_
33-41	4523-4533	pathogenic	abstract[233]|abstract[234]|object[235]|person[236]|abstract[237]	new[233]|new[234]|giv[235]|giv[236]|new[237]	_	_
33-42	4534-4543	canonical	abstract[233]|abstract[234]|object[235]|person[236]|abstract[237]	new[233]|new[234]|giv[235]|giv[236]|new[237]	_	_
33-43	4544-4550	splice	abstract[233]|abstract[234]|object[235]|person[236]|abstract[237]|organization|object[239]	new[233]|new[234]|giv[235]|giv[236]|new[237]|new|new[239]	_	_
33-44	4551-4555	site	abstract[233]|abstract[234]|object[235]|person[236]|abstract[237]|object[239]	new[233]|new[234]|giv[235]|giv[236]|new[237]|new[239]	_	_
33-45	4556-4564	variants	abstract[233]|abstract[234]|object[235]|person[236]|abstract[237]	new[233]|new[234]|giv[235]|giv[236]|new[237]	_	_
33-46	4565-4568	not	_	_	_	_
33-47	4569-4576	covered	_	_	_	_
33-48	4577-4579	by	_	_	_	_
33-49	4580-4586	Sanger	person	giv	_	_
33-50	4587-4590	and	_	_	_	_
33-51	4591-4596	panel	person|abstract[242]	new|new[242]	_	_
33-52	4597-4607	approaches	abstract[242]	new[242]	_	_
33-53	4608-4609	(	_	_	_	_
33-54	4610-4612	e.	_	_	_	_
33-55	4613-4615	g.	_	_	_	_
33-56	4616-4617	,	_	_	_	_
33-57	4618-4622	ADA2	_	_	_	_
33-58	4623-4624	:	_	_	_	_
33-59	4625-4627	c.	abstract	new	_	_
33-60	4628-4636	-47+2T>C	_	_	_	_
33-61	4637-4638	)	_	_	_	_
33-62	4639-4640	;	_	_	_	_
33-63	4641-4643	or	_	_	_	_
33-64	4644-4649	large	_	_	_	_
33-65	4650-4661	chromosomal	animal	new	_	_
33-66	4662-4676	rearrangements	_	_	_	_
33-67	4677-4678	,	_	_	_	_
33-68	4679-4691	encompassing	_	_	_	_
33-69	4692-4699	several	abstract[245]	giv[245]	_	_
33-70	4700-4705	genes	abstract[245]	giv[245]	_	_
33-71	4706-4708	in	abstract[245]	giv[245]	_	_
33-72	4709-4717	patients	abstract[245]|person[246]	giv[245]|giv[246]	_	_
33-73	4718-4722	with	abstract[245]|person[246]	giv[245]|giv[246]	_	_
33-74	4723-4730	complex	abstract[245]|person[246]|abstract[247]	giv[245]|giv[246]|new[247]	_	_
33-75	4731-4741	phenotypes	abstract[245]|person[246]|abstract[247]	giv[245]|giv[246]|new[247]	_	_
33-76	4742-4743	.	_	_	_	_

#Text=In those circumstances , an MSM could help find the best appropriate strategy in accordance with the patient ’s phenotype .
34-1	4744-4746	In	_	_	_	_
34-2	4747-4752	those	abstract[248]	new[248]	_	_
34-3	4753-4766	circumstances	abstract[248]	new[248]	_	_
34-4	4767-4768	,	_	_	_	_
34-5	4769-4771	an	abstract[249]	giv[249]	_	_
34-6	4772-4775	MSM	abstract[249]	giv[249]	_	_
34-7	4776-4781	could	_	_	_	_
34-8	4782-4786	help	_	_	_	_
34-9	4787-4791	find	_	_	_	_
34-10	4792-4795	the	abstract[250]	giv[250]	_	_
34-11	4796-4800	best	abstract[250]	giv[250]	_	_
34-12	4801-4812	appropriate	abstract[250]	giv[250]	_	_
34-13	4813-4821	strategy	abstract[250]	giv[250]	_	_
34-14	4822-4824	in	abstract[250]	giv[250]	_	_
34-15	4825-4835	accordance	abstract[250]|abstract[251]	giv[250]|new[251]	_	_
34-16	4836-4840	with	abstract[250]|abstract[251]	giv[250]|new[251]	_	_
34-17	4841-4844	the	abstract[250]|abstract[251]|abstract[253]	giv[250]|new[251]|giv[253]	coref	38-10[272_253]
34-18	4845-4852	patient	abstract[250]|abstract[251]|person[252]|abstract[253]	giv[250]|new[251]|giv[252]|giv[253]	_	_
34-19	4853-4855	’s	abstract[250]|abstract[251]|person[252]|abstract[253]	giv[250]|new[251]|giv[252]|giv[253]	_	_
34-20	4856-4865	phenotype	abstract[250]|abstract[251]|abstract[253]	giv[250]|new[251]|giv[253]	_	_
34-21	4866-4867	.	_	_	_	_

#Text=The role of the reference centers is to determine whether or not the clinical/anamnesis/genealogical tree is compatible with a known AID .
35-1	4868-4871	The	abstract[254]	new[254]	coref	36-11[261_254]
35-2	4872-4876	role	abstract[254]	new[254]	_	_
35-3	4877-4879	of	abstract[254]	new[254]	_	_
35-4	4880-4883	the	abstract[254]|place[256]	new[254]|giv[256]	_	_
35-5	4884-4893	reference	abstract[254]|person|place[256]	new[254]|giv|giv[256]	_	_
35-6	4894-4901	centers	abstract[254]|place[256]	new[254]|giv[256]	_	_
35-7	4902-4904	is	_	_	_	_
35-8	4905-4907	to	_	_	_	_
35-9	4908-4917	determine	_	_	_	_
35-10	4918-4925	whether	_	_	_	_
35-11	4926-4928	or	_	_	_	_
35-12	4929-4932	not	_	_	_	_
35-13	4933-4936	the	object[257]	new[257]	_	_
35-14	4937-4968	clinical/anamnesis/genealogical	object[257]	new[257]	_	_
35-15	4969-4973	tree	object[257]	new[257]	_	_
35-16	4974-4976	is	_	_	_	_
35-17	4977-4987	compatible	_	_	_	_
35-18	4988-4992	with	_	_	_	_
35-19	4993-4994	a	abstract[258]	giv[258]	_	_
35-20	4995-5000	known	abstract[258]	giv[258]	_	_
35-21	5001-5004	AID	abstract[258]	giv[258]	_	_
35-22	5005-5006	.	_	_	_	_

#Text=If compatibility does not seem to be the case , the role is to evaluate the potential added value to perform the NGS .
36-1	5007-5009	If	_	_	_	_
36-2	5010-5023	compatibility	abstract	new	_	_
36-3	5024-5028	does	_	_	_	_
36-4	5029-5032	not	_	_	_	_
36-5	5033-5037	seem	_	_	_	_
36-6	5038-5040	to	_	_	_	_
36-7	5041-5043	be	_	_	_	_
36-8	5044-5047	the	abstract[260]	new[260]	_	_
36-9	5048-5052	case	abstract[260]	new[260]	_	_
36-10	5053-5054	,	_	_	_	_
36-11	5055-5058	the	abstract[261]	giv[261]	_	_
36-12	5059-5063	role	abstract[261]	giv[261]	_	_
36-13	5064-5066	is	_	_	_	_
36-14	5067-5069	to	_	_	_	_
36-15	5070-5078	evaluate	_	_	_	_
36-16	5079-5082	the	abstract[262]	new[262]	coref	37-2[264_262]
36-17	5083-5092	potential	abstract[262]	new[262]	_	_
36-18	5093-5098	added	abstract[262]	new[262]	_	_
36-19	5099-5104	value	abstract[262]	new[262]	_	_
36-20	5105-5107	to	_	_	_	_
36-21	5108-5115	perform	_	_	_	_
36-22	5116-5119	the	place[263]	giv[263]	coref	37-14[266_263]
36-23	5120-5123	NGS	place[263]	giv[263]	_	_
36-24	5124-5125	.	_	_	_	_

#Text=If this value appears to be low , the reference center recommends that no NGS be conducted in discussion with geneticists .
37-1	5126-5128	If	_	_	_	_
37-2	5129-5133	this	abstract[264]	giv[264]	_	_
37-3	5134-5139	value	abstract[264]	giv[264]	_	_
37-4	5140-5147	appears	_	_	_	_
37-5	5148-5150	to	_	_	_	_
37-6	5151-5153	be	_	_	_	_
37-7	5154-5157	low	_	_	_	_
37-8	5158-5159	,	_	_	_	_
37-9	5160-5163	the	person[265]	new[265]	_	_
37-10	5164-5173	reference	person[265]	new[265]	_	_
37-11	5174-5180	center	person[265]	new[265]	_	_
37-12	5181-5191	recommends	_	_	_	_
37-13	5192-5196	that	_	_	_	_
37-14	5197-5199	no	place[266]	giv[266]	_	_
37-15	5200-5203	NGS	place[266]	giv[266]	_	_
37-16	5204-5206	be	_	_	_	_
37-17	5207-5216	conducted	_	_	_	_
37-18	5217-5219	in	_	_	_	_
37-19	5220-5230	discussion	abstract[267]	new[267]	coref	38-3[269_267]
37-20	5231-5235	with	abstract[267]	new[267]	_	_
37-21	5236-5247	geneticists	abstract[267]|person	new[267]|giv	_	_
37-22	5248-5249	.	_	_	_	_

#Text=Thus , this discussion decreases the number of individuals whose phenotype is not typically enough .
38-1	5250-5254	Thus	_	_	_	_
38-2	5255-5256	,	_	_	_	_
38-3	5257-5261	this	abstract[269]	giv[269]	_	_
38-4	5262-5272	discussion	abstract[269]	giv[269]	_	_
38-5	5273-5282	decreases	_	_	_	_
38-6	5283-5286	the	quantity[270]	new[270]	_	_
38-7	5287-5293	number	quantity[270]	new[270]	_	_
38-8	5294-5296	of	quantity[270]	new[270]	_	_
38-9	5297-5308	individuals	quantity[270]|person	new[270]|new	_	_
38-10	5309-5314	whose	abstract[272]	giv[272]	_	_
38-11	5315-5324	phenotype	abstract[272]	giv[272]	_	_
38-12	5325-5327	is	_	_	_	_
38-13	5328-5331	not	_	_	_	_
38-14	5332-5341	typically	_	_	_	_
38-15	5342-5348	enough	_	_	_	_
38-16	5349-5350	.	_	_	_	_
